1. 880PSubgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy. (23rd October 2018) Authors: Procopio, G; Cognetti, F; Miceli, R; Milella, M; Mosca, A; Chiuri, V E; Bearz, A; Morelli, F; Ortega, C; Atzori, F; Passalacqua, R; Ratta, R; de Braud, F G M; Cappelletti, V; Verzoni, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells. (20th April 2018) Authors: Cappelletti, V; Miodini, P; Reduzzi, C; Alfieri, S; Daidone, M G; Licitra, L; Locati, L D Journal: Annals of oncology Issue: Volume 29:Number 7(2018) Page Start: 1598 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗